These data strongly support further investigation of the CXCL1–CXCR2 interaction in rodent models of AD with Aβ (and tau) abnormalities to determine if this ligand–receptor pair is a novel target for therapeutic intervention. This evidence concerns the gene CXCL1 and Alzheimer disease.